Month: April 2026

MENLO PARK, Calif., April 1, 2026 /PRNewswire/ — Global talent solutions and business consulting firm Robert Half (NYSE: RHI) has again been selected as one of Fortune’s 100 Best Companies to Work For^®. Robert Half’s consulting subsidiary, Protiviti, is also included on the highly competitive list.

Fortune 100 Best Companies to Work For recognizes top organizations with innovative programs that reflect a genuine commitment to meeting employee needs inside and outside the workplace, as validated by employee feedback. Great Place To Work^® analyzed anonymous survey responses from more than 1.3 million professionals from Great Place To Work Certified^™ companies with at least 1,000 employees in the U.S. Organizations are assessed on their efforts to create supportive, high-performance work experiences for every person in the organization.

“This recognition reflects our ongoing commitment to fostering a people-first approach,” said M. Keith Waddell, president and chief executive officer of Robert Half. “Our core values—integrity, inclusion, innovation and commitment to success—are embedded in our organizational culture, empowering employees to reach their full potential both personally and professionally.”

The survey also examined how responses varied across demographic groups and roles, providing insight into the consistency of the employee experience. Key indicators include accessibility to leaders, connection with colleagues and pride in work.

“Our focus remains on our people, with a commitment to supporting their growth and providing an environment where they can thrive and perform at their best,” said JoLynn Conway-James, senior executive director and chief administrative officer at Robert Half. “We take pride in our workplace culture, where employees feel valued, heard and supported.”

Robert Half is committed to supporting employees at every stage of their career and in the moments that matter most to them. In addition to ongoing recognition and mentoring programs, the company has invested in tools and technologies to improve the employee experience, including:

• Personalized learning paths: The organization customizes professional development and training by role and department, allowing employees to focus on the skills that support their growth and career advancement.
• Enhanced onboarding experience: By leveraging technology to simplify workflows, Robert Half offers an interactive and comprehensive onboarding experience for new employees and hiring managers, reducing manual effort and improving consistency across the organization.
• Self-service options: To help employees get faster answers to benefits questions, financial well-being needs (including retirement savings) and company policies, Robert Half offers a range of self-service tools, complemented by high-touch, individualized support.

FAQs
How does Robert Half support its employees?
Robert Half’s employee commitment focuses on supporting its people by prioritizing well-being, investing in career growth, fostering connection and empowering them to make a meaningful impact.

What innovative programs is Robert Half pursuing to build a world-class employee experience?
Through customized development opportunities and leadership pathways, a new performance review platform and continuous listening strategy, and emerging technologies that combine human judgment with AI-driven efficiency, employees are empowered to work smarter and stay future-ready.

Does Robert Half help clients build strong workplace cultures?
Robert Half helps clients build strong workplace cultures by delivering forward-looking talent solutions and consulting services aligned with their organizational goals.

About Robert Half
Robert Half is the world’s first and largest specialized talent solutions and business consulting firm, connecting highly skilled job seekers with rewarding opportunities at great companies. We offer contract talent and permanent placement solutions in the fields of finance and accounting, technology, marketing and creative, legal, and administrative and customer support, and we also provide executive search services. Robert Half is the parent company of Protiviti^®, a global consulting firm that delivers internal audit, risk, business and technology consulting solutions. In the past 12 months, Robert Half, including Protiviti, has been named one of the Fortune^® Most Admired Companies™ and one of Newsweek’s Most Charitable Companies. Explore talent solutions, research and insights at RobertHalf.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/robert-half-recognized-by-fortune-as-one-of-the-100-best-companies-to-work-for-302731529.html

SOURCE Robert Half

Adults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial¹

Foundayo, Lilly’s second FDA-approved obesity medicine, will be available via LillyDirect^® with free home delivery, starting at $25 per month with commercial coverage and $149 for self-pay

INDIANAPOLIS, April 1, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available via LillyDirect^®, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers.

“People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment,” said Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. “With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials – addressing both the clinical realities of obesity and the practical challenges patients face every day.”

Supported by the rigorous ATTAIN clinical trial program, Foundayo was proven to help people lose weight and keep it off. In the ATTAIN-1 trial, individuals taking the highest dose of Foundayo and who stayed on treatment lost an average of 27.3 pounds (12.4%) compared to 2.2 pounds (0.9%) with placebo.¹ Participants taking Foundayo, regardless of trial completion, lost an average of 25 pounds (11.1%), compared to 5.3 pounds (2.1%) with placebo.² In the ATTAIN program, Foundayo also led to reductions in many markers of cardiovascular risk, including waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across all doses.

“Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isn’t serious enough for treatment. We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications,” said David A. Ricks, chair and CEO of Eli Lilly and Company. “As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world.”

Lilly is committed to making Foundayo accessible and affordable. Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card.³ Individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose. Additionally, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026.

Use of Foundayo with other GLP-1 receptor agonist medicines is not recommended. It is not known whether Foundayo is safe and effective for use in children. Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath. If you have any of these symptoms, tell your health care provider. The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Please see Indication and Safety Summary with Warning below and full Prescribing Information and Medication Guide.

“There is no single path that works for everyone living with overweight or obesity,” said Joe Nadglowski, president and CEO of the Obesity Action Coalition. “New treatment options expand choice and help more people find care that fits their lives, their goals and where they are in their journey – whether they’re just starting to explore treatment or looking for a different long-term approach.”

Lilly has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each country shortly after approval.

For more information about Foundayo, please visit www.foundayo.lilly.com. 

About Foundayo (orforglipron)⁴
Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.⁵ Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About ATTAIN-1 and ATTAIN-2 clinical trial program
The ATTAIN Phase 3 global clinical development program for orforglipron has enrolled more than 4,500 people with obesity or overweight across two global registration trials.

ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in body weight reduction from baseline after 72 weeks.

ATTAIN-2 (NCT05872620) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes. The trial randomized over 1,600 participants across the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico to receive various doses of orforglipron or placebo along with healthy diet and physical activity. The primary objective of the study was to demonstrate that orforglipron is superior to placebo in mean body weight change from baseline at 72 weeks.

INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo™ (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

• Foundayo should not be used with other GLP-1 receptor agonist medicines.
• It is not known if Foundayo is safe and effective for use in children.

Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

• Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
• Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn’t go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

• Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works.
• Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
• If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo.
• Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

Review these questions with your healthcare provider:

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

• Take Foundayo exactly as your healthcare provider tells you to.
• Use Foundayo with a reduced-calorie diet and increased physical activity.
• Take Foundayo by mouth 1 time each day, with or without food.
• Swallow tablets whole. Do not break, crush, or chew the tablet.
• If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day.
• Do not take more than 1 tablet per day.
• If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment.
• If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo^™ is a trademark of Eli Lilly and Company.

Endnotes and References 

1. The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and modifications) for 72 weeks without initiating prohibited weight management treatments.⁴
2. The treatment-regimen estimand represents the estimated average treatment effect regardless of adherence to study intervention or initiation of prohibited weight management treatments.⁴
3. Terms and conditions apply. Learn more at foundayo.lilly.com.
4. Foundayo. Prescribing Information. Lilly USA, LLC.
5. Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832. https://doi.org/10.1007/s13300-024-01554-1. Epub 2024 Feb 24. PMID: 38402332; PMCID: PMC10951152.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo as a treatment for adults with obesity or some adults with overweight who also have weight-related medical problems and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that Foundayo will receive additional regulatory approvals, or that Foundayo will be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Trademarks and Trade Names 
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ^® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

CMAT-04552 04/2026 ©Lilly USA, LLC 2026. All rights reserved.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html

SOURCE Eli Lilly and Company

Novel Transdermal Curcumin Formulation Demonstrates Pain Reduction and Improved Quality of Life in Phase 1b Clinical Trial

Study published in Frontiers in Pain Research reports significant reduction in knee pain with topical curcumin formulation

SUMMIT, N.J., April 1, 2026 /PRNewswire/ — Vascarta Inc. today announced the publication of results from a randomized, double-blind, placebo-controlled clinical trial evaluating VAS-101, the company’s investigational topical/transdermal curcumin gel, for the treatment of knee pain associated with osteoarthritis. The study appears in the peer-reviewed journal Frontiers in Pain Research. Frontiers | The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study

The clinical trial demonstrated that participants using VAS-101 experienced statistically significant reductions in knee pain compared with placebo, along with a favorable safety and tolerability profile.

Dr. Adrian Lopresti, Managing Director of Clinical Trials Australia and principal investigator, stated, “The results of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants. VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis.”

Study Design
The randomized, double-blind, placebo-controlled trial enrolled 60 adults aged 45–75 with knee osteoarthritis. Participants applied either 0.1 mL VAS-101 or 0.1 mL placebo gel to the affected knee every other day for 28 days.

Researchers assessed outcomes using several validated measures, including:

• KOOS pain subscale (primary endpoint)
• Daily pain ratings
• Performance-based physical function tests
• Use of rescue oral pain medication

Key Findings
Results from the study showed that VAS-101 produced meaningful improvements in pain outcomes compared with placebo:

• Significant improvement in KOOS pain score (β: 5.12; 95% CI: 0.47–9.77; p = 0.041)
• Significant reduction in daily pain ratings (p = 0.005)
• 39.3% of participants using VAS-101 reported feeling “much improved” or “very much improved,” compared with 13.3% in the placebo group (p = 0.019)
• 32.1% of participants achieved a Minimal Clinically Important Difference in symptoms, compared with 13.3% with placebo

VAS-101 was well tolerated, with no significant adverse reactions reported. Temporary skin staining, a known characteristic of topical curcumin, was observed but resolved within two to three days after discontinuation.

Implications
The study suggests that topical delivery of curcumin may offer a promising non-oral therapeutic approach to managing osteoarthritis-related knee pain, potentially addressing limitations associated with oral formulations.

While further research with larger patient populations and longer treatment durations is needed, these findings highlight the potential role of VAS-101 in managing osteoarthritis pain,” said Joel Friedman, M.D., Ph.D., inventor of Vascarta’s patented transdermal drug delivery technology, Professor Emeritus at Albert Einstein College of Medicine, and Chief Scientific Officer.

Chairman and CEO Richard Prince, Ph.D. added: “These data indicate the potential of VAS-101 to become the standard of care in osteoarthritis. We intend to accelerate our efforts in the development of VAS-101 for osteoarthritis with the anticipated filing of an Investigational New Drug Application to the United States Food & Drug Administration later this year.” 

About Knee Osteoarthritis
Knee osteoarthritis is a degenerative joint condition affecting millions of adults worldwide. It is characterized by chronic pain, stiffness, reduced mobility, and progressive deterioration of joint cartilage.

About VAS-101
VAS-101 is an investigational topical curcumin formulation developed and patented by Vascarta. It is designed to deliver curcumin through the skin directly into affected joints, potentially providing localized and enhanced systemic anti-inflammatory and analgesic effects.

About Vascarta
Vascarta Inc. is a clinical-stage pharmaceutical company focused on developing therapies to address chronic pain and inflammation. The company’s proprietary drug delivery platform supports a growing pipeline of therapies targeting inflammatory diseases and cancer.

The company’s lead candidate, Vasceptor® (VAS-101), is a topically applied transdermal formulation utilizing curcumin as its active pharmaceutical ingredient. By bypassing the gastrointestinal tract and first-pass liver metabolism, the transdermal route may enhance curcumin delivery into systemic circulation compared with oral formulations.

Contacts for further information:
Dr. Richard Prince
Chairman, CEO & President
rprince@vascarta.com

Mr. David Hymson
Communications
dhymson@vascarta.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vascarta-announces-positive-clinical-trial-results-for-topicaltransdermal-curcumin-gel-vas-101-in-knee-osteoarthritis-302731447.html

SOURCE Vascarta Inc

• Genesis Inspiration Foundation marks major milestone in long‑term commitment to creativity, access, and opportunity for young people nationwide

NEW YORK, April 1, 2026 /PRNewswire/ — Genesis Inspiration Foundation, a 501(c)(3) nonprofit organization committed to supporting education through the arts, announced it will award more than $3 million in 2026 to 91 youth arts organizations across the United States, a commitment that brings the Foundation’s total philanthropic giving to more than $16 million since 2018. Established to expand access to youth arts education, Genesis Inspiration Foundation represents a long‑term investment in creativity, helping ensure that young people, regardless of background, have opportunities to explore, learn, and express themselves through the arts.

“Over the past 10 years, Genesis has been building a brand built on design, performance, and purpose,” said Tedros Mengiste, chief operating officer of Genesis Motor North America. “Through Genesis Inspiration Foundation, we are making a sustained investment in arts education to help young people unlock their creativity, expand what they believe is possible, and build skills that will serve them for a lifetime.”

Genesis Inspiration Foundation provides support for youth arts programs nationwide, aiming to increase accessibility and foster creativity, especially within under-resourced communities. The arts play a critical role in fostering creativity, confidence, and critical thinking—skills essential to shaping future innovators and leaders.

“Genesis Inspiration Foundation exists to expand access to arts education and ensure young people have the opportunity to discover their creative potential,” said Walter Dawson, board chair, Genesis Inspiration Foundation. “Reaching more than $16 million in total giving reflects our commitment to creating opportunity, fostering creativity, and supporting the organizations that inspire the next generation.”

A portion of every new Genesis vehicle sold helps fund youth arts education through the Genesis Inspiration Foundation, with additional support provided by Genesis Motor America. Together, these contributions help thousands of children each day realize the full power of their imaginations while reinforcing Genesis’ commitment to contributing meaningfully to the communities it serves.

The complete list of grant recipients will be announced later this year.

Genesis Inspiration Foundation

Genesis Inspiration Foundation is a 501(c)(3) nonprofit organization committed to connecting youth to the transformative power of the arts. Our mission is to improve educational outcomes by providing access to arts programs that engage and inspire children in under-resourced communities. Founded in 2018, the Genesis Inspiration Foundation has awarded over $16 million in grants to expand youth arts at museums, schools, and community organizations nationwide. With the support of Genesis and its retailers, we are introducing children to a new world of possibilities. To learn more, visit us online at www.genesisinspirationfoundation.org.

Genesis Motor North America

Genesis is a new global automotive brand that delivers the highest standards of design, safety, refined performance, and innovation while looking towards a more sustainable future. Drawing from its cultural heritage and distinctly Korean hospitality, Genesis crafts experiences focused on customers as “son-nim”, or honored guests.

Genesis Motor North America offers a growing range of award-winning SUV, sedan, and electric models through its network of more than 200 independent U.S. retailers, in addition to its more than 30 Canadian agency distributors. Genesis now counts more than 100 standalone retail facilities across the North American region, with dozens more in development. Consumers can discover the brand through its many retail points, at Genesis House, the brand’s flagship space in New York City, or online at www.genesis.com.

Please visit our media site for the latest news at www.genesisnewsusa.com (United States) and www.genesisnews.ca (Canada).

View original content to download multimedia:https://www.prnewswire.com/news-releases/genesis-inspiration-foundation-celebrates-16-million-invested-in-youth-arts-education-302731205.html

SOURCE Genesis Motor America

• Genesis Inspiration Foundation marks major milestone in long‑term commitment to creativity, access, and opportunity for young people nationwide

NEW YORK, April 1, 2026 /PRNewswire/ — Genesis Inspiration Foundation, a 501(c)(3) nonprofit organization committed to supporting education through the arts, announced it will award more than $3 million in 2026 to 91 youth arts organizations across the United States, a commitment that brings the Foundation’s total philanthropic giving to more than $16 million since 2018. Established to expand access to youth arts education, Genesis Inspiration Foundation represents a long‑term investment in creativity, helping ensure that young people, regardless of background, have opportunities to explore, learn, and express themselves through the arts.

“Over the past 10 years, Genesis has been building a brand built on design, performance, and purpose,” said Tedros Mengiste, chief operating officer of Genesis Motor North America. “Through Genesis Inspiration Foundation, we are making a sustained investment in arts education to help young people unlock their creativity, expand what they believe is possible, and build skills that will serve them for a lifetime.”

Genesis Inspiration Foundation provides support for youth arts programs nationwide, aiming to increase accessibility and foster creativity, especially within under-resourced communities. The arts play a critical role in fostering creativity, confidence, and critical thinking—skills essential to shaping future innovators and leaders.

“Genesis Inspiration Foundation exists to expand access to arts education and ensure young people have the opportunity to discover their creative potential,” said Walter Dawson, board chair, Genesis Inspiration Foundation. “Reaching more than $16 million in total giving reflects our commitment to creating opportunity, fostering creativity, and supporting the organizations that inspire the next generation.”

A portion of every new Genesis vehicle sold helps fund youth arts education through the Genesis Inspiration Foundation, with additional support provided by Genesis Motor America. Together, these contributions help thousands of children each day realize the full power of their imaginations while reinforcing Genesis’ commitment to contributing meaningfully to the communities it serves.

The complete list of grant recipients will be announced later this year.

Genesis Inspiration Foundation

Genesis Inspiration Foundation is a 501(c)(3) nonprofit organization committed to connecting youth to the transformative power of the arts. Our mission is to improve educational outcomes by providing access to arts programs that engage and inspire children in under-resourced communities. Founded in 2018, the Genesis Inspiration Foundation has awarded over $16 million in grants to expand youth arts at museums, schools, and community organizations nationwide. With the support of Genesis and its retailers, we are introducing children to a new world of possibilities. To learn more, visit us online at www.genesisinspirationfoundation.org.

Genesis Motor North America

Genesis is a new global automotive brand that delivers the highest standards of design, safety, refined performance, and innovation while looking towards a more sustainable future. Drawing from its cultural heritage and distinctly Korean hospitality, Genesis crafts experiences focused on customers as “son-nim”, or honored guests.

Genesis Motor North America offers a growing range of award-winning SUV, sedan, and electric models through its network of more than 200 independent U.S. retailers, in addition to its more than 30 Canadian agency distributors. Genesis now counts more than 100 standalone retail facilities across the North American region, with dozens more in development. Consumers can discover the brand through its many retail points, at Genesis House, the brand’s flagship space in New York City, or online at www.genesis.com.

Please visit our media site for the latest news at www.genesisnewsusa.com (United States) and www.genesisnews.ca (Canada).

View original content to download multimedia:https://www.prnewswire.com/news-releases/genesis-inspiration-foundation-celebrates-16-million-invested-in-youth-arts-education-302731205.html

SOURCE Genesis Motor America

• Larger, Wider, and Roomier than previous generation. Delivers best-in-class capability: More legroom (including best-in-class rear legroom), headroom, shoulder-and-hip room adds up to more passenger and cargo room
• Multiple powertrain options: Choice of 2.0-liter normally aspirated, 1.6-liter turbocharged and new HEV make Seltos the only vehicle in its segment with three powertrain options
• Sophisticated and Capable: New available Multi-terrain AWD¹ mode, and up to 8.1 inches of available ground clearance.
• Next generation technology: Connected Car Navigation Cockpit (ccNC) with over-the-air update capability². Available Entertainment and Data Services³ with YouTube and Netflix⁴ streaming; available custom display themes for all 30 NBA teams and some of Disney’s© most iconic brands⁵
• Big SUV Capability: Boxy upright profile, larger passenger and cargo capacity, newly integrated standard Kia Add Gear cargo organization
• Telluride-inspired Design Cues: Chiseled design, available auto-flush door handles, modern, premium interior
• Advanced and easy-to-use dash layout, adopting the new Telluride’s nearly 30 inches of digital cockpit system: Standard dual 12.3-inch screen displays and an available 5-inch display for climate control; intuitive touch and manual controls
• Big on features: Seltos boasts new available content typically found in upmarket segments, such as available Panoramic sunroof, Surround View Monitor⁶, Blind Spot View Monitor, memory power driver’s seat with 4-way lumbar
• Expanded ADAS⁷: Standard Hands-On Detection, Forward Collision Avoidance Assist with Junction Turning, Smart Cruise Control with stop & go⁸, Parking Distance Warning Front/Rear
• Coming Soon: The 2027 Seltos ICE is targeted to go on sale in the second quarter of 2026

NEW YORK, April 1, 2026 /PRNewswire/ — Today at the 2026 New York International Auto Show, Kia America hosted the North American debut of the all-new 2027 Seltos. Building on the nimble, versatile attributes of the first-generation Seltos, the second-generation Seltos brings together modern standard and available features that buyers are looking for, and some they might not expect in this vehicle class. With in-car tech, ADAS features, and other content sooner found in upmarket segments, the 2027 Seltos aims to raise the bar for the small SUV segment. With more cabin space, more cargo space, and more screen space than the previous generation, the 2027 Seltos delivers impressive content for those who crave turning any drive into an adventure.

Experience the interactive Multimedia News Release here: https://www.multivu.com/kia/9375051-en-new-2027-kia-seltos 

“With the launch of the second-generation Kia Seltos the goal was to develop a small SUV that would raise the bar for the segment,” said Orth Hedrick, executive director, Product Planning, Kia North America. “Packed with many standard and available features found on the all-new 2027 Telluride, the 2027 Seltos offers a thought-provoking purchase consideration for cost-conscious shoppers who crave adventure.”

In addition to being larger than its predecessor, the five-passenger 2027 Seltos brings in new features that elevate the small SUV segment, such as flush door handles, an available panoramic sunroof, available Surround View Monitor⁶, and an available up to nearly 30 inches of total combined screens⁹ with Kia’s latest ccNC infotainment tech, including Over-the-Air updates². These features, as well as the available memory power seats, Multi-Mode AWD, and Forward Collision Avoidance Assist with Junction Turning are all features that can also be found in Kia’s Telluride flagship SUV. In addition to carrying over the normally aspirated 2.0-liter and turbocharged 1.6-liter engines, the 2027 Seltos offers a new hybrid powertrain that combines performance and hybrid efficiency, including a Kia first electric-AWD (e-AWD)¹ on a Hybrid SUV. More information on the HEV will be shared closer to the vehicle’s planned on-sale date in late 2026.

The 2.0-liter will be offered in LX, S, EX and X-Line, while the 1.6T will be available in X-Line trim only. The 2.0-liter and 1.6T are expected to arrive in the United States in Q2 2026. Pricing will be announced closer to their on-sale date.

Exterior Design: The Authentic Modern SUV

The Seltos is the latest vehicle to benefit from Kia’s Opposites United design philosophy, bringing together contrasting elements of nature and humanity to create thoughtful, expressive designs. The new Seltos also takes styling cues from the flagship Telluride SUV to carve out its own legacy as a small SUV that embodies a dynamic and energetic persona. Inspired by the design language of the Telluride, amber DRL frames the front fascia, while bold angles, clean lines, combines with flush door handles delivers a strong distinctive presence. At its core, the 2027 Seltos is designed for versatility. It is longer, wider, and boasts a wheelbase that is 2.4 inches greater than its predecessor.

The standard wheels are 16-inch alloys, and the Seltos X-Line 2.0L comes with larger 18-inch alloy wheels, with black 19-inch wheels on the X-Line 1.6T and X-Line HEV when equipped with e-AWD. The X-Line trim also features unique bumpers and side sills with Piano Black trim and dark gun metal accents, underscoring its distinctive persona. New colors include Terrain Brown, Frost Blue and Snow White Pearl with a distinctive black roof. Ground clearance has increased from 7.3 inches to an available 8.1 inches.

Interior Design: Functionally Sophisticated

The larger exterior dimensions of the new 2027 Seltos result in a more spacious cabin and the upright greenhouse allows for exceptional outward visibility. The cabin’s overall design is highly influenced by Kia’s “Opposites United” philosophy. This includes the squared-off steering wheel, open center console design, and clean lines that visually connect the Seltos to the Telluride. The Seltos interior is further punctuated by “blades” that extend the aesthetic of the dash into the front doors, creating an enveloping effect around the driver and front passenger.

Drawing inspiration from the Telluride and EV9, the Seltos Hybrid features a stalk-mounted shifter and push-button start. This is an ergonomic shift controller that moves right to where your hand naturally rests at the steering wheel. In doing so, the center console is left open, with plenty of space for water bottles, phones, and other small items.

In addition to its unique exterior, X-Line comes with an exclusive monotone black interior with SynTex upholstery and Telluride-inspired mesh headrests. The X-Line seats also boast standard four-way lumbar support and the X-Line Prestige Package includes front driver Relaxation Seat.

The longer wheelbase and greater overall length result in more legroom front and rear with 1-inch increase in rear legroom. Overall head room, hip room and shoulder room also increase.

Cargo capacity is improved, with an estimated 64.1 cu-ft. behind the first row and an estimated 27.8 cu-ft. behind the second row. The new Seltos also features a height adjustable and multi-folding luggage board and new flexible Kia Add Gear attachment points that offer drivers more storage solutions for their next adventure.

Tech Suite: Functionally Sophisticated

The all-new Seltos has thoughtful deployment of technology designed for daily life, highlighted by the digital dash display. It includes a standard 12.3-inch digital touchscreen display and is available with a 12.3-inch instrument display and 5-inch climate display panel⁹. The ccNC setup features over-the-air² update capability. Wireless Apple CarPlay¹⁰ and Android Auto¹¹ are standard across all trims.

Kia’s generative AI assistant³ allows for a more natural conversation, and can be initiated simply by saying, “Hey, Kia…”. Kia Connect¹² allows consumers to use their compatible smartphones to send remote commands such as lock, unlock, cool, heat and start the vehicle¹³.

The 2027 Seltos is available with Entertainment and Data Services¹⁴, which supports streaming for Disney+, Netflix, and YouTube. There are also available display themes for some of Disney’s© most iconic brands, which will be introduced throughout 2026. Display themes are also available for all 30 NBA teams, as well as themes to celebrate Kia’s sponsorship of the 2026 FIFA World Cup¹⁵. Kia myQ Connected Garage offers fully integrated, convenient garage access that lets you remotely manage and control your garage door through your Kia touchscreen display¹⁶. Experience all the new ways to stay connected and entertained with these upcoming features and more, all available in the Kia Connect Store.

The 2027 Seltos can help keep devices charged with multiple standard USB-C ports that span both rows. The front-row ports are nestled between the center console and the climate controls and include a media port and two charging ports. The rear-seat charging ports are integrated into the first-row seatbacks for easy access.

Seltos Powertrains: Three Ways to Adventure

The Seltos is the only offering in the segment to offer three powertrain options starting with the 2.0-liter four-cylinder engine paired with Kia’s Intelligent Variable Transmission (IVT). For those seeking lively pickup, the turbocharged 1.6-liter four-cylinder engine develops an estimated 190 horsepower with standard advanced Multi-Mode AWD system. This engine routes power through an 8-speed automatic transmission with manual control. The 2.0L powertrain is offered with front-wheel drive or an available advanced Multi-Mode AWD system¹. Depending on trim, 8.1 inches of ground clearance, the Seltos bolsters its capability within the segment.

Rounding out the lineup is a hybrid powertrain, which is a first for the Seltos. An advanced 1.6-liter four-cylinder hybrid engine is paired with a 6-speed dual clutch transmission designed to enhance both performance and efficiency. Front-wheel drive HEV improves driving efficiency while available e-AWD¹, Kia first on a HEV SUV, provides more power with on-demand all-wheel drive capability to provide a more rewarding driving experience. More information on the Seltos HEV will become available later this year. Official fuel economy figures for these versatile powertrains will be available closer to their respective on-sale dates.

Seltos ADAS: Elevated Peace of Mind

The all-new 2027 Seltos comes with a comprehensive list of standard and available Advanced Driver Assistance Systems (ADAS)¹ bringing features typically found in more upscale SUVs. This includes new-to-Seltos features such as standard Forward Collision Avoidance (FCA) Assist with Junction Turning, standard Front and Reverse Parking Distance Warning, and newly available Side Parking Distance Warning with Reverse Parking Collision Avoidance. The Seltos now offers an optional 360° Surround-View Monitor, as well as Kia’s Blind-Spot View Monitor¹⁷, which presents a video feed display of the left or right blind spot area on the digital display when the corresponding turn-signal is activated. This Blind Spot View Monitor and 360° Surround-View Monitor are optional on the X-Line trim.

The list of standard ADAS features includes Lane Keeping Assist, Lane Departure Warning, Driver Attention Warning with Leading Vehicle Departure Alert, High-Beam Assist, Intelligent Speed-Limit Warning, and Forward Collision Avoidance Assist with pedestrian and cyclist detection. It also comes standard with Lane Following Assist 2. Available ADAS features include Intelligent Speed-Limit Assist, Blind-Spot Collision Avoidance Assist, Rear Cross Traffic Warning, Rear Cross Traffic Avoidance and Safe Exit Warning¹⁸, which is designed to provide an alert to occupants if it detects another vehicle approaching as they are exiting the vehicle.

Seltos Availability

The all-new 2027 Kia Seltos 2.0L and 1.6T is anticipated to go on sale in the U.S. in Q2 2026, with the HEV expected to arrive in late Q4. Pricing, timing availability, specific trim details, and EPA-rated fuel economy estimates are subject to future announcements.

Kia America – about us

Headquartered in Irvine, California, Kia America continues to top automotive quality surveys. Kia is recognized as one of the TIME World’s Most Sustainable Companies of 2025. Kia serves as the “Official Automotive Partner” of the NBA and WNBA and offers a range of gasoline, hybrid, plug-in hybrid, and electric vehicles sold through a network of nearly 800 dealers in the U.S., including several SUVs proudly assembled in America*.

For media information, including photography, visit www.kiamedia.com. To receive custom email notifications for press releases the moment they are published, subscribe at www.kiamedia.com/us/en/newsalert

* Select trims of the all-electric EV6 and EV9 all-electric three-row SUV, Sportage (excludes HEV and PHEV models), Sorento (excludes HEV and PHEV models), and Telluride are assembled in the United States from U.S. and globally sourced parts.

¹ No system, no matter how advanced, can compensate for all driver error and/or driving conditions. Always drive safely.

² Over-the-Air features and updates may require an additional cost and may vary by model, model year, and trim level. Features, specifications, and fees are subject to change. Kia Connect subscription is required and Kia Connect terms and conditions apply.

³ Kia Connect subscription required. Use of the feature is subject to the Kia Connect Terms of Service and Privacy Policy. May be currently unavailable for vehicles purchased or sold in Massachusetts that are not eligible for Kia Connect. Kia does not make any warranties about the accuracy of the information provided. Distracted driving can result in a loss of vehicle control. When operating a vehicle, never use a vehicle system that takes your focus away from safe vehicle operation.

⁴ YouTube is a trademark of Google LLC. Netflix is a trademark of Netflix Inc.

⁵ Display Themes are only available on models that have the latest ccNC (Connected Car Navigation Cockpit) based infotainment system. An active Kia Connect subscription is required to utilize Display Themes. Without and active Kia Connect subscription, Display Themes will not be operational. Once purchased, Display Themes are limited to use on the specific vehicle tied to purchase and cannot be transferred to other vehicles.

⁶ When engaged, Surround View Monitor is not a substitute for safe driving, and may not display all objects around vehicle. Always drive safely and use caution.

⁷ Advanced Driver Assistance Systems are not substitutes for safe driving, and may not detect all objects around the vehicle. Always drive safely and use caution.

⁸ When engaged, Smart Cruise Control with Stop and Go is not a substitute for safe driving and cruise-control procedures. This is not an auto-pilot feature. Always drive safely and use caution. The Smart Cruise Control system may not detect every object in front of the vehicle.

⁹ Comprised of a 12.3-in. instrument display, 12.3-in. touchscreen infotainment display, and 5-in. climate display.

¹⁰ Apple CarPlay runs on smartphone cellular data service. Normal data rates apply. Apple and CarPlay are trademarks of Apple, Inc.

¹¹ Android Auto™: Vehicle user interface is a product of Google, and its terms and privacy statements apply. Requires the Android Auto app on Google Play and an Android-compatible smartphone running Android™ 5.0 Lollipop or higher. Data plan rates apply. Android Auto is a trademark of Google LLC.

¹² Kia Connect subscription required. Use of the feature is subject to the Kia Connect Terms of Service and Privacy Policy. May be currently unavailable for vehicles purchased or sold in Massachusetts that are not eligible for Kia Connect. Kia does not make any warranties about the accuracy of the information provided. Distracted driving can result in a loss of vehicle control. When operating a vehicle, never use a vehicle system that takes your focus away from safe vehicle operation. Purchase/lease of a 2026 Kia with Kia Connect includes a complimentary 3-year subscription to the Kia Connect Ultimate package, starting from new vehicle retail sale/lease date as recorded by the dealer. Use of Kia Connect is subject to agreement to the Kia Connect Privacy Policy (available at https://owners.kia.com/us/en/privacy-policy.html) and Terms of Service (available at https://owners.kia.com/us/en/terms-of-service.html). Kia Connect may currently be unavailable for some Model Year 2022 and newer vehicles sold or purchased in Massachusetts. Kia Connect features may vary by model, model year, and trim level. Features, specifications, and fees are subject to change.

¹³ Do not use remote climate control or remote start if vehicle is in an enclosed area (e.g., closed garage) or a partially enclosed area without ventilation. Close all doors leading from adjacent living areas to the vehicle area before executing a remote climate control or remote start command. Remote feature support varies by model, model year and trim.

¹⁴ Additional subscriptions may be required for streaming services. Vehicle must be parked for video streaming and gaming features.

¹⁵ FIFA Themes are available through July 31, 2026

¹⁶ Kia myQ Connected Garage is available only on vehicles with a ccNC head unit. Kia Connect and myQ accounts are required to activate your myQ-enabled garage door opener. This feature depends on various other factors in the vehicle such as LTE network coverage to transmit data. Coverage not available everywhere. Certain services may collect location information and data usage applies. Kia Connect terms and conditions apply. Kia myQ Connected Garage is subject to a functioning link between Kia Connect and myQ accounts, as well as myQ systems availability. Speed of the network communication is dependent on the systems and LTE network coverage.

¹⁷ When engaged, Blind-Spot View Monitor is not a substitute for safe driving and may not display all objects around vehicle. Always drive safely and use caution.

¹⁸ When engaged, Safe Exit Assist is not a substitute for one’s attention and may not detect all objects surrounding the vehicle. Always pay attention to traffic and to the area around your vehicle when exiting the vehicle.

 

 

 

 

 

View original content:https://www.prnewswire.com/news-releases/introducing-the-all-new-2027-kia-seltos-big-suv-capability-puts-small-suv-segment-on-notice-302730794.html

SOURCE Kia America